What are the side effects of melphalan/melphalan for injection?

Melphalan for injection/Melphalan flufenamide In the clinical application, side effects are an aspect that needs to be focused on. In clinical studies of multiple myeloma (MM), the most common side effects include fatigue, nausea, diarrhea, fever, and respiratory infection, with the incidence rates of these adverse reactions exceeding 20%. In addition, abnormalities found in laboratory examinations are relatively common, with the incidence rates of laboratory abnormalities such as leukopenia, thrombocytopenia, lymphopenia, neutropenia, hemoglobin decrease and creatinine increase all exceeding 50%. These side effects may have an impact on the patient's overall health and require close monitoring during treatment.

Patients using injectable melphalan who have a history of severe allergic reactions must avoid using this drug to prevent possible serious adverse consequences. During treatment, patients may develop serious complications such as thrombocytopenia and neutropenia, which may lead to an increased risk of bleeding and infection. At the same time, patients may also develop anemia, which can further aggravate their frail condition. Therefore, care teams need to pay special attention to these potential health risks for patients being treated with this drug.

In addition to common side effects, the use of injectable melphalan also requires caution about the risk of secondary malignant tumors. Certain uses of this drug may trigger the development of new tumors, so regular monitoring and evaluation should be ensured during treatment to allow early detection of any abnormalities. In addition, embryo-fetal toxicity is an important warning, and special attention should be paid to pregnant women or female patients who may become pregnant to avoid potential harm to the fetus during treatment.